Hence, the APE1/Ref-1 redox domain inhibitor APX3330 provides an opportunity to target specific redox mechanisms of the oxidative stress response associated with intestinal inflammation and provide further understanding of its role in IBD pathogenesis. The gene discussed is APEX1; the disease is inflammatory bowel disease.